Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun 30;2(1):e000248.
doi: 10.1136/openhrt-2015-000248. eCollection 2015.

Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis

Rhanderson N Cardoso  1 , Alexandre M Benjo  2 , James J DiNicolantonio  3 , Daniel C Garcia  1 , Francisco Y B Macedo  4 , Georges El-Hayek  5 , Girish N Nadkarni  6 , Sebastiano Gili  7 , Mario Iannaccone  7 , Ioannis Konstantinidis  6 , John P Reilly  2
Affiliations

Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis

Rhanderson N Cardoso et al. Open Heart. .

Abstract

Background: Dual antiplatelet therapy is the standard of care after coronary stent placement but increases the bleeding risk. The effects of proton pump inhibitors (PPIs) on clopidogrel metabolism have been described, but the clinical significance is not yet definitive. We aimed to do an updated meta-analysis comparing outcomes in patients receiving clopidogrel with and without PPIs.

Methods: We systematically searched PubMed, Scopus and the Cochrane Central Register of Controlled Trials for randomised controlled trials (RCTs) and controlled observational studies in patients taking clopidogrel stratified by concomitant PPI use. Heterogeneity was examined with the Cochran Q test and I(2) statistics; p values inferior to 0.10 and I(2) >25% were considered significant for heterogeneity.

Results: We included 39 studies with a total of 214 851 patients, of whom 73 731 (34.3%) received the combination of clopidogrel and a PPI. In pooled analysis, all-cause mortality, myocardial infarction, stent thrombosis and cerebrovascular accidents were more common in patients receiving both drugs. However, among 23 552 patients from eight RCTs and propensity-matched studies, there were no significant differences in mortality or ischaemic events between groups. The use of PPIs in patients taking clopidogrel was associated with a significant reduction in the risk of gastrointestinal bleeding.

Conclusions: The results of our meta-analysis suggest that PPIs are a marker of increased cardiovascular risk in patients taking clopidogrel, rather than a direct cause of worse outcomes. The pharmacodynamic interaction between PPIs and clopidogrel most likely has no clinical significance. Furthermore, PPIs have the potential to decrease gastrointestinal bleeding in clopidogrel users.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flow diagram of study selection.
Figure 2
Figure 2
Forest plot of studies examining outcomes between patients taking proton pump inhibitor ( PPIs) with clopidogrel and those taking only clopidogrel: (A) overall mortality; (B) myocardial infarction.
Figure 3
Figure 3
Forest plot of studies examining outcomes between patients taking proton pump inhibitor (PPIs) with clopidogrel and those taking only clopidogrel: (A) definite stent thrombosis; (B) need for revascularisation; (C) cerebrovascular accidents; (D) acute coronary syndromes.
Figure 4
Figure 4
Forest plot of studies examining gastrointestinal bleeding between patients taking proton pump inhibitor (PPI) with clopidogrel and those taking only clopidogrel.
Figure 5
Figure 5
Forest plots of randomised controlled trials and propensity score matched studies examining outcomes between patients taking proton pump inhibitor (PPIs) with clopidogrel and those taking only clopidogrel: (A) overall mortality; (B) acute coronary syndromes; (C) myocardial infarction; (D) need for revascularisation; (E) cerebrovascular accidents; (F) gastrointestinal bleeding.
See this image and copyright information in PMC

References

    1. Levine GN, Bates ER, Blankenship JC et al. . 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011;124:e574–651. 10.1161/CIR.0b013e31823ba622 - DOI - PubMed
    1. O'Gara PT, Kushner FG, Ascheim DD et al. . 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e362–425. 10.1161/CIR.0b013e3182742cf6 - DOI - PubMed
    1. Writing Committee Members Jneid H, Anderson JL, Wright RS et al. , American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2012;126:875–910. 10.1161/CIR.0b013e318256f1e0 - DOI - PubMed
    1. Yusuf S, Zhao F, Mehta SR et al. . Clopidogrel in unstable angina to prevent recurrent events trial I: effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502. 10.1056/NEJMoa010746 - DOI - PubMed
    1. Steinhubl SR, Berger PB, Mann JT III et al. , CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Observation CICftRoED: early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411–20. 10.1001/jama.288.19.2411 - DOI - PubMed

LinkOut - more resources